Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7 Lung Neoplasms 4 Colorectal Neoplasms 3 Carcinoma, Hepatocellular 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Glioblastoma 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Select Advanced Solid Tumors 1 Sarcoma 1 Recurrence 1 Prostate Adenocarcinoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Glioma 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1

Interventions

Gemcitabine 3 Cisplatin 3 Irinotecan 2 Fluorouracil 2 Capecitabine 2 tremelimumab 1 pamiparib 1 durvalumab 1 brigimadlin 1 atezolizumab 1 Temozolomide 1 Surgical Procedures, Operative 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 IMC-001 1 Blood Specimen Collection 1 ARX788 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Biliary Tract Neoplasms × atezolizumab × Clear all

NCT03818997 2020-02-05

DYNAMIC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡